Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care-;announces the publication of ...

DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a life sciences company focused on molecular hydrogen and AI diagnostics for brain health, today announced that it has filed a provisional ...

Annovis Bio Inc. ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

Dogwood's expanded pipeline includes three late-stage assets: Halneuron ®, currently in Phase 2b development for chemotherapy ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA ® (capsaicin) 8% topical system in post-surgical neuropathic ...

The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...